- Trump bump may be over as US stocks get slammed on Friday.
- Pharmaceutical stocks like Amgen and Merck have both sold off.
- Trump names anti-vaccine presidential candidate RFK Jr. to nation's top healthcare post.
- Kennedy believes that vaccines cause autism and wants to use his perch to carry out further testing.
Pharmaceutical stocks are tripping over themselves to sell off on Friday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his choice to lead the Department of Health & Human Services (HHS). Kennedy, who bears the name of his father who was assassinated on the campaign trail in 1968, is the most famous vaccine skeptic in the United States (as well as being from its most famous political family) and heavily distrusts the pharmaceutical industry, US agriculture and the processed foods industry.
Two members of the Dow Jones Industrial Average (DJIA), Amgen (AMGN) and Merck (MRK), have both sold off more than 3% on Friday in light of the news. The general idea is that Kennedy might be able to obstruct approvals for new drugs, discontinue vaccines provided to US patients on Medicare and Medicaid, as well as promote a general distrust of drugs among the citizenry who are its end customers.
The Dow Jones sank 0.7% on Friday, which was much better than the S&P 500 (-1.4%) and the NASDAQ (-2.4%).
Amgen, Merck stock news
Similar to Trump’s “Make America Great Again” tagline, which he revived from his first term for the recent election, Kennedy has been touting “Make America Healthy Again”. One of his major policies, which he has already begun to roll out in a campaign video, is to ban a number of additives and dyes found in US processed foods, which he blames for US obesity and declining life expectancy.
A longtime environmental lawyer, Kennedy holds a number of views that place him squarely in the conspiracy theory camp concerning US health. Besides blaming sexual dysphoria on herbicides, he wants to remove fluoride from public drinking water, blames 5G wi-fi for brain damage, and thinks the covid pandemic was engineered to sidestep certain Jewish and Chinese populations.
His most famous health interest is his decades-long campaign against childhood vaccines, which he blames for causing autism. Scientists overwhelmingly don’t believe this to be true, but Kennedy founded a nonprofit called Children’s Health Defense that has been influential across the US in pushing that notion.
As head of HHS, Kennedy vows to perform new testing on vaccines to find if there is a link between them and autism. HHS is in charge of the Food & Drug Administration (FDA), which is part of the government apparatus that has the authority to approve vaccines and pharmaceuticals before they enter the market.
Additionally, as the government department that oversees the trillions of dollars that the US spends via Medicare (elderly patients) and Medicaid (those without access to private health insurance), Kennedy could have a role in reducing government funding of certain blockbuster drugs that he thinks might have been improperly approved. Kennedy has called pharmaceutical regulators “corrupt” on a number of occasions.
Amgen stock has already sold off this week after it came to light that its experimental weightloss drug MariTide might be causing patients to lose bone mineral density. This drug is Amgen’s attempt to compete with Novo Nordisk (NOVO) and Eli Lilly (LLY) in the exploding weightloss industry.
Amgen, Merck stock charts
Merck stock has broken through 2024 support at $112 and then 2023 support at $100. Now the market is rotating back toward 2022 levels where sell-offs were often halted in the $83 to $85 range.
MRK daily stock chart
Amgen stock has been cratering so hard in the past week that it already had fallen below support at $296. That price level was tested on multiple occasions this past summer. Now expect AMGN stock to move swiftly toward 2023 support near $260.
AMGN daily stock chart
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD struggles to hold above 1.1000 after mixed EU data
EUR/USD is having a difficult time stabilizing above 1.1000 in the European session on Monday. The Eurozone Sentix Investor Confidence slumped to -19.5 in April while the annual February Retail Sales jumped 2.3%, limiting the pair's upside despite the broad US Dollar weakness.
GBP/USD reverses below 1.2900 despite US Dollar weakness
GBP/USD fails to sustain the recovery and reverses below 1.2900 in European trading on Monday. The pair shrugs off broad US Dollar weakness as risk sentiment takes a fresh hit, with European traders hitting their desks, weighing on the risk sensitive Pound Sterling.
Gold price holds above $3,000 amid a global meltdown; bulls seem non-committed
Gold price attracts some sellers near the $3,055 support-turned-resistance and stalls its intraday recovery from the $2,972-2,971 area, or a nearly four-week low touched earlier this Monday. Investors continue to unwind their bullish positions to cover losses from a broader meltdown across the global financial markets
Solana Price Forecast: Bears gain momentum as SOL falls below $100
Solana (SOL) extends its loss by over 7% and falls below the $100 mark at the time of writing on Monday after crashing 15.15% last week. Coinglass data shows that SOL’s leveraged traders wiped out nearly $70 million in liquidations in the last 24 hours.
Strategic implications of “Liberation Day”
Liberation Day in the United States came with extremely protectionist and inward-looking tariff policy aimed at just about all U.S. trading partners. In this report, we outline some of the more strategic implications of Liberation Day and developments we will be paying close attention to going forward.
The Best brokers to trade EUR/USD
SPONSORED Discover the top brokers for trading EUR/USD in 2025. Our list features brokers with competitive spreads, fast execution, and powerful platforms. Whether you're a beginner or an expert, find the right partner to navigate the dynamic Forex market.